GlassScriptPhysician profile
Michael Stamper
NPI 1831318187
$2,722.37
in general payments reported to CMS, 2019-2025
31 companies · $753 in 2025
The $753 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $456 · 2022: $612 · 2023: $394 · 2024: $507 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,654.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $700.29 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $578.82 | 2021-2025 | |
| Pfizer INC. | $146.38 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.44 | 2021-2025 | |
| Lilly USA, LLC | $138.57 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $132.86 | 2021-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.35 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $96.15 | 2021-2024 | Breztri |
| Idorsia Pharmaceuticals US INC | $70.14 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $65.60 | 2021-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $57.22 | 2022-2024 | |
| Verona Pharma, INC. | $47.22 | 2025 | Ohtuvayre |
| Ironshore Pharmaceuticals INC. | $45.95 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.36 | 2024-2025 | Caplyta |
| Ucb, INC. | $32.67 | 2025 | Briviact |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $32.14 | 2025 | Zoryve |
| Collegium Pharmaceutical, INC. | $29.85 | 2025 | Jornay Pm |
| Abbott Laboratories | $29.56 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.55 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $23.45 | 2023 | Gvoke Hypopen |
| Optinose US, INC. | $20.70 | 2024 | |
| Sanofi-Aventis U.S. LLC | $20.39 | 2021 | |
| Axsome Therapeutics, INC. | $18.23 | 2025 | Auvelity |
| Dexcom, INC. | $17.29 | 2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.47 | 2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $16.21 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $14.86 | 2021 | |
| Exact Sciences Corporation | $14.05 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $13.91 | 2023 | Vaxelis, Gardasil 9, Pneumovax 23 |
| Janssen Pharmaceuticals, INC | $13.15 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stamper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.